BiotechTube

RDC-0313 (ALKS 33) + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Binge Eating Disorder

Conditions

Binge Eating Disorder

Trial Timeline

May 1, 2010 → Jun 1, 2011

NCT ID
NCT01098435

About RDC-0313 (ALKS 33) + Placebo

RDC-0313 (ALKS 33) + Placebo is a phase 2 stage product being developed by Alkermes for Binge Eating Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01098435. Target conditions include Binge Eating Disorder.

What happened to similar drugs?

2 of 8 similar drugs in Binge Eating Disorder were approved

Approved (2) Terminated (1) Active (5)
✅Duloxetine + PlaceboEli LillyApproved
✅Solriamfetol + PlaceboJazz PharmaceuticalsApproved
🔄Zonegran + sugar pillEisaiPhase 3
🔄dasotraline 4mg + dasotraline 6mg + PlaceboSumitomo PharmaPhase 3
🔄DasotralineSumitomo PharmaPhase 3
❌Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + PlaceboNovo NordiskPhase 3
🔄Solriamfetol 75mg, 150 mg, or 300 mgAxsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01098435Phase 2Completed

Competing Products

11 competing products in Binge Eating Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine + PlaceboEli LillyApproved
43
Zonegran + sugar pillEisaiPhase 3
40
Dasotraline + PlaceboSumitomo PharmaPhase 2/3
38
dasotraline 4mg + dasotraline 6mg + PlaceboSumitomo PharmaPhase 3
40
DasotralineSumitomo PharmaPhase 3
40
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + PlaceboNovo NordiskPhase 3
32
Solriamfetol + PlaceboJazz PharmaceuticalsApproved
36
Sodium OxybateJazz PharmaceuticalsPhase 2/3
35
Solriamfetol 75mg, 150 mg, or 300 mgAxsome TherapeuticsPhase 3
44
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
44
ACT-539313 + PlaceboIdorsiaPhase 2
29